<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02616510</url>
  </required_header>
  <id_info>
    <org_study_id>13-010</org_study_id>
    <nct_id>NCT02616510</nct_id>
  </id_info>
  <brief_title>Primary Ovarian Insufficiency, Polycystic Ovary Syndrome &amp; the CardiOvascular Risk Profile</brief_title>
  <acronym>POPCORn</acronym>
  <official_title>Primary Ovarian Insufficiency, Polycystic Ovary Syndrome &amp; the CardiOvascular Risk Profile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The polycystic ovary syndrome (PCOS) is the most common endocrinopathy amongst women of
      reproductive age. PCOS is associated with various cardiovascular risk factors such as
      obesity, glucose intolerance, dyslipidemia hypertension and the metabolic syndrome. Whether
      these increased cardiovascular risk factors result in the development of actual
      cardiovascular disease in later life remains to be established.

      Women with premature ovarian insufficiency (POI), experience menopause prior to the age of 40
      years. Women with POI may exhibit dyslipidemia. A young age at menopause has been previously
      associated with increased cardiovascular morbidity and mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular risk profile will be assessed in women with PCOS and POI &gt; 45 years of age,
      consisting of:

      fasting serum and urine analyses blood pressure, length, weight, waist circumference, hip
      circumference ECG carotid intima media thickness cardiac ultrasound

      spare serum, plasma and urine will be stored in -80 degrees celsius biobank.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>carotid intima media thickness</measure>
    <time_frame>10 years post diagnosis</time_frame>
    <description>ultrasound measurement of thickness of carotid wall (mean IMT), presence of atherosclerotic plaques (yes/no, location)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>dyslipidemia</measure>
    <time_frame>10 years post diagnosis</time_frame>
    <description>serum measurement of low density lipoprotein cholesterol, triglycerides, total cholesterol, high density lipoprotein cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin and glucose levels</measure>
    <time_frame>10 years post diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>10 years post diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>homocysteine</measure>
    <time_frame>10 years post diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>uric acid</measure>
    <time_frame>10 years post diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>androgen levels</measure>
    <time_frame>10 years post diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electrocardiogram (ECG)</measure>
    <time_frame>10 years post diagnosis</time_frame>
    <description>documentation of heart rythm, potential signs of ischemia (ST segment), length PR, QRS, QT, RR interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac ultrasound (hypertrophy)</measure>
    <time_frame>10 years post diagnosis</time_frame>
    <description>measurement of left ventricular ejection fraction and left ventricular mass,</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>PCOS</arm_group_label>
    <description>Rotterdam criteria (at least 2 out of three criteria present) oligo-anovulation polycystic ovarian morphology hyperandrogenism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>POI</arm_group_label>
    <description>amenorrhea of at least 4 months prior to age 40 years, with follicle stimulating hormone (FSH) levels above 40 IU/L</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cardiovascular screening</intervention_name>
    <description>cardiovascular screening: serum, urine, ECG, carotid intima media thickness (IMT), cardiac ultrasound</description>
    <arm_group_label>PCOS</arm_group_label>
    <arm_group_label>POI</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, serum, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        women with PCOS according to rotterdam criteria (2 or more of these criteria)

          -  oligo/anovulation

          -  polycystic ovarian morphology

          -  hyperandrogenism

        Women with POI amenorrhea of at least 4 months prior to age 40 years with FSH levels above
        40 IU/L
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age above 45 years

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Fauser, prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bart Fauser, prof</last_name>
    <phone>+31887557524</phone>
    <email>b.c.fauser@umcutrecht.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine Daan, doctor</last_name>
    </contact>
    <investigator>
      <last_name>Nadine Daan, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2015</study_first_submitted>
  <study_first_submitted_qc>November 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2015</study_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Bart CJM Fauser</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Turner Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

